{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T23:05:27Z","timestamp":1792623927240,"version":"4.5.0"},"reference-count":116,"publisher":"Springer Science and Business Media LLC","issue":"S3","license":[{"start":{"date-parts":[[2024,12,9]],"date-time":"2024-12-09T00:00:00Z","timestamp":1733702400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,12,9]],"date-time":"2024-12-09T00:00:00Z","timestamp":1733702400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Allergy Asthma Clin Immunol"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Atopic dermatitis (AD) is a common, chronic skin disorder that can significantly impact the quality of life (QoL) of affected individuals as well as their families. Although the pathogenesis of the disorder is not yet completely understood, it appears to result from the complex interplay between defects in skin barrier function, environmental and infectious agents, and immune dysregulation. There are no diagnostic tests for AD; therefore, the diagnosis is based on specific clinical criteria that take into account the patient\u2019s history and clinical manifestations. Successful management of the disorder requires a multifaceted approach that involves education, optimal skin care practices, anti-inflammatory treatment with topical corticosteroids, topical calcineurin inhibitors (TCIs) and\/or phosphodiesterase-4 (PDE-4) inhibitors, the management of pruritus, and the treatment of skin infections. Systemic immunosuppressive agents may also be used, but are generally reserved for severe flare-ups or more difficult-to-control disease. Newer systemic agents, such as Janus Kinase (JAK) inhibitors and biologics, have a more favourable safety and efficacy profile than the older, traditional systemic immunosuppressives. Topical corticosteroids are the first-line pharmacologic treatments for AD, and evidence suggests that these agents may also be beneficial for the prophylaxis of disease flare-ups. Although the prognosis for patients with AD is generally favourable, those patients with severe, widespread disease and concomitant atopic conditions, such as asthma and allergic rhinitis, are likely to experience poorer outcomes. Newer systemic agents have been approved which are greatly improving the QoL of these patients.<\/jats:p>","DOI":"10.1186\/s13223-024-00927-2","type":"journal-article","created":{"date-parts":[[2024,12,9]],"date-time":"2024-12-09T12:42:19Z","timestamp":1733748139000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Atopic dermatitis"],"prefix":"10.1186","volume":"20","author":[{"given":"Stuart","family":"Carr","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Pratt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fred","family":"White","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wade","family":"Watson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,9]]},"reference":[{"key":"927_CR1","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1542\/peds.2007-2232","volume":"122","author":"AC Krakowski","year":"2008","unstructured":"Krakowski AC, Eichenfield LF, Dohil MA. Management of atopic dermatitis in the pediatric population. Pediatrics. 2008;122:812\u201324.","journal-title":"Pediatrics"},{"key":"927_CR2","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1097\/ACI.0b013e3282ffd6cc","volume":"8","author":"SP McKenna","year":"2008","unstructured":"McKenna SP, Doward LC. Quality of life of children with atopic dermatitis and their families. Curr Opin Allergy Clin Immunol. 2008;8:228\u201331.","journal-title":"Curr Opin Allergy Clin Immunol"},{"issue":"12","key":"927_CR3","doi-asserted-by":"crossref","first-page":"2653","DOI":"10.1007\/s13555-022-00819-6","volume":"12","author":"AN Fasseeh","year":"2022","unstructured":"Fasseeh AN, Elezbawy B, Korra N, Tannira M, Dalle H, Aderian S, Abaza S, Kal\u00f3 Z. Burden of atopic dermatitis in adults and adolescents: a systematic literature review. Dermatol Ther (Heidelb). 2022;12(12):2653\u201368.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"2","key":"927_CR4","first-page":"97","volume":"41","author":"V Gonzalez-Uribe","year":"2023","unstructured":"Gonzalez-Uribe V, Vidaurri-de la Cruz H, Gomez-Nu\u00f1ez A, Leyva-Calderon JA, Mojica-Gonzalez ZS. Comorbidities & burden of disease in atopic dermatitis. Asian Pac J Allergy Immunol. 2023;41(2):97\u2013105.","journal-title":"Asian Pac J Allergy Immunol"},{"issue":"1","key":"927_CR5","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1111\/j.1365-4632.2004.02345.x","volume":"45","author":"M Barbeau","year":"2006","unstructured":"Barbeau M, Bpharm HL. Burden of atopic dermatitis in Canada. Int J Dermatol. 2006;45(1):31\u20136.","journal-title":"Int J Dermatol"},{"issue":"2","key":"927_CR6","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.jaci.2016.06.002","volume":"138","author":"G Egawa","year":"2016","unstructured":"Egawa G, Kabashima K. Multifactorial skin barrier deficiency and atopic dermatitis: essential topics to prevent the atopic march. J Allergy Clin Immunol. 2016;138(2):350\u20138.","journal-title":"J Allergy Clin Immunol"},{"issue":"6","key":"927_CR7","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1016\/j.jaci.2016.10.004","volume":"138","author":"T Nomura","year":"2016","unstructured":"Nomura T, Kabashima K. Advances in atopic dermatitis in 2015. J Allergy Clin Immunol. 2016;138(6):1548\u201355.","journal-title":"J Allergy Clin Immunol"},{"key":"927_CR8","doi-asserted-by":"crossref","first-page":"S128","DOI":"10.1016\/j.jaci.2003.09.033","volume":"112","author":"JM Spergel","year":"2003","unstructured":"Spergel JM, Paller AS. Atopic dermatitis and the atopic march. J Allergy Clin Immunol. 2003;112:S128\u201339.","journal-title":"J Allergy Clin Immunol"},{"issue":"4","key":"927_CR9","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1016\/j.jaci.2015.10.049","volume":"137","author":"T Tsakok","year":"2016","unstructured":"Tsakok T, Marrs T, Mohsin M, Baron S, du Toit G, Till S, Flohr C. Does atopic dermatitis cause food allergy? A systematic review. J Allergy Clin Immunol. 2016;137(4):1071\u20138.","journal-title":"J Allergy Clin Immunol"},{"issue":"12","key":"927_CR10","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1111\/j.1440-1754.2011.02125.x","volume":"48","author":"DE Campbell","year":"2012","unstructured":"Campbell DE. Role of food allergy in childhood atopic dermatitis. J Paediatr Child Health. 2012;48(12):1058\u201364.","journal-title":"J Paediatr Child Health"},{"issue":"3","key":"927_CR11","doi-asserted-by":"crossref","first-page":"181","DOI":"10.4168\/aair.2016.8.3.181","volume":"8","author":"JH Lee","year":"2016","unstructured":"Lee JH, Son SW, Cho SH. A comprehensive review of the treatment of atopic eczema. Allergy Asthma Immunol Res. 2016;8(3):181\u201390.","journal-title":"Allergy Asthma Immunol Res"},{"issue":"10023","key":"927_CR12","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/S0140-6736(15)00149-X","volume":"387","author":"S Weidinger","year":"2016","unstructured":"Weidinger S, Novak N. Atopic dermatitis. Lancet. 2016;387(10023):1109\u201322.","journal-title":"Lancet"},{"key":"927_CR13","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1016\/j.jaci.2022.10.023","volume":"151","author":"CF Schuler","year":"2023","unstructured":"Schuler CF, Billi AC, Maverakis E, Tsoi LC, Gudjonsson JE. Novel insights into atopic dermatitis. J Allergy Clin Immunol. 2023;151:1145\u201354.","journal-title":"J Allergy Clin Immunol"},{"key":"927_CR14","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1016\/j.jaci.2020.02.021","volume":"145","author":"DYM Leung","year":"2020","unstructured":"Leung DYM, Berdyshev E, Goleva E. Cutaneous barrier dysfunction in allergic diseases. J Allergy Clin Immunol. 2020;145:1485\u201397.","journal-title":"J Allergy Clin Immunol"},{"key":"927_CR15","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.jid.2020.05.100","volume":"141","author":"SJ Brown","year":"2021","unstructured":"Brown SJ. What have we learned from GWAS for atopic dermatitis? J Invest Dermatol. 2021;141:19\u201322.","journal-title":"J Invest Dermatol"},{"key":"927_CR16","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1016\/j.jaci.2021.07.043","volume":"149","author":"E Sliz","year":"2022","unstructured":"Sliz E, Huilaja L, Pasanen A, Laisk T, Reimann E, Magi R, et al. Uniting biobank resources reveals novel genetic pathways modulating susceptibility for atopic dermatitis. J Allergy Clin Immunol. 2022;149:1105\u2013e129.","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"927_CR17","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.anai.2020.08.002","volume":"126","author":"V Wang","year":"2021","unstructured":"Wang V, Boguniewicz J, Boguniewicz M, Ong PY. The infectious complications of atopic dermatitis. Ann Allergy Asthma Immunol. 2021;126(1):3\u201312.","journal-title":"Ann Allergy Asthma Immunol"},{"key":"927_CR18","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1016\/j.jaci.2021.03.015","volume":"147","author":"KR Bartemes","year":"2021","unstructured":"Bartemes KR, Kita H. Roles of innate lymphoid cells (ILCs) in allergic diseases: the 10-year anniversary for ILC2s. J Allergy Clin Immunol. 2021;147:1531\u201347.","journal-title":"J Allergy Clin Immunol"},{"key":"927_CR19","doi-asserted-by":"crossref","unstructured":"Klaeschen AS, N\u00fcmm TJ, Herrmann N, Leib N, Maintz L, Sakai T et al. JAK1\/2 inhibition impairs the development and function of inflammatory dendritic epidermal cells in atopic dermatitis. J Allergy Clin Immunol. 2021;147:2202-12.e8.","DOI":"10.1016\/j.jaci.2020.11.041"},{"key":"927_CR20","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1111\/bjd.19580","volume":"184","author":"MR Laughter","year":"2021","unstructured":"Laughter MR, Maymone MBC, Mashayekhi S, Arents BWM, Karimkhani C, Langan SM, et al. The global burden of atopic dermatitis: lessons from the global burden of Disease Study, 1990\u20132017. Br J Dermatol. 2021;184:304\u20139.","journal-title":"Br J Dermatol"},{"issue":"4","key":"927_CR21","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1016\/j.jaci.2014.12.013","volume":"135","author":"M Kelleher","year":"2015","unstructured":"Kelleher M, Dunn-Galvin A, Hourihane JO, Murray D, Campbell LE, McLean WH, Irvine AD. Skin barrier dysfunction measured by transepidermal water loss at 2 days and 2 months predates and predicts atopic dermatitis at 1 year. J Allergy Clin Immunol. 2015;135(4):930\u20135.","journal-title":"J Allergy Clin Immunol"},{"issue":"4","key":"927_CR22","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1016\/j.jaci.2015.12.1312","volume":"137","author":"MM Kelleher","year":"2016","unstructured":"Kelleher MM, Dunn-Galvin A, Gray C, Murray DM, Kiely M, Kenny L, McLean WH, Irvine AD, Hourihane JO. Skin barrier impairment at birth predicts food allergy at 2 years of age. J Allergy Clin Immunol. 2016;137(4):1111\u20136.","journal-title":"J Allergy Clin Immunol"},{"issue":"2","key":"927_CR23","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.anai.2019.04.020","volume":"123","author":"JI Silverberg","year":"2019","unstructured":"Silverberg JI. Comorbidities and the impact of atopic dermatitis. Ann Allergy Asthma Immunol. 2019;123(2):144\u201351.","journal-title":"Ann Allergy Asthma Immunol"},{"key":"927_CR24","doi-asserted-by":"crossref","first-page":"101","DOI":"10.4168\/aair.2015.7.2.101","volume":"7","author":"BY Pyun","year":"2015","unstructured":"Pyun BY. Natural history and risk factors of atopic dermatitis in children. Allergy Asthma Immunol Res. 2015;7:101\u20135.","journal-title":"Allergy Asthma Immunol Res"},{"key":"927_CR25","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1056\/NEJMra074081","volume":"358","author":"T Bieber","year":"2008","unstructured":"Bieber T. Mechanisms of disease: atopic dermatitis. N Engl J Med. 2008;358:1483\u201394.","journal-title":"N Engl J Med"},{"key":"927_CR26","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1111\/cea.12406","volume":"45","author":"PE Martin","year":"2015","unstructured":"Martin PE, Eckert JK, Koplin JJ, Lowe AJ, Gurrin LC, Dharmage SC, et al. Which infants with eczema are at risk of food allergy? Results from a population-based cohort. Clin Exp Allergy. 2015;45:255\u201364.","journal-title":"Clin Exp Allergy"},{"key":"927_CR27","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.anai.2017.10.037","volume":"120","author":"DA Hill","year":"2018","unstructured":"Hill DA, Spergel JM. The atopic march: critical evidence and clinical relevance. Ann Allergy Asthma Immunol. 2018;120:131\u20137.","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"10","key":"927_CR28","doi-asserted-by":"crossref","first-page":"e1001748","DOI":"10.1371\/journal.pmed.1001748","volume":"11","author":"DC Belgrave","year":"2014","unstructured":"Belgrave DC, Granell R, Simpson A, Guiver J, Bishop C, Buchan I, et al. Developmental profiles of eczema, wheeze, and rhinitis: two population-based birth cohort studies. PLoS Med. 2014;11(10):e1001748.","journal-title":"PLoS Med"},{"issue":"1","key":"927_CR29","doi-asserted-by":"crossref","first-page":"4","DOI":"10.4168\/aair.2019.11.1.4","volume":"11","author":"EH Tham","year":"2019","unstructured":"Tham EH, Leung DY. Mechanisms by which atopic dermatitis predisposes to food allergy and the atopic march. Allergy Asthma Immunol Res. 2019;11(1):4\u201315.","journal-title":"Allergy Asthma Immunol Res"},{"issue":"5","key":"927_CR30","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1111\/jdv.18919","volume":"37","author":"MO Christensen","year":"2023","unstructured":"Christensen MO, Barakji YA, Loft N, Khatib CM, Egeberg A, Thomsen SF, et al. Prevalence of and association between atopic dermatitis and food sensitivity, food allergy and challenge-proven food allergy: a systematic review and meta-analysis. J Eur Acad Dermatol Venereol. 2023;37(5):984\u20131003.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"927_CR31","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.jaci.2014.10.007","volume":"135","author":"HA Brough","year":"2015","unstructured":"Brough HA, Liu AH, Sicherer S, Makinson K, Douiri A, Brown SJ, et al. Atopic dermatitis increases the effect of exposure to peanut antigen in dust on peanut sensitization and likely peanut allergy. J Allergy Clin Immunol. 2015;135(1):164\u201370.","journal-title":"J Allergy Clin Immunol"},{"key":"927_CR32","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.jaci.2006.03.045","volume":"118","author":"CA Akdis","year":"2006","unstructured":"Akdis CA, Akdis M, Bieber T, Bindslev-Jensen C, Boguniewicz M, Eigenmann P, et al. European Academy of Allergology and Clinical Immunology\/American Academy of Allergy, Asthma and Immunology. Diagnosis and treatment of atopic dermatitis in children and adults: European Academy of Allergology and Clinical Immunology\/American Academy of Allergy, Asthma and Immunology\/PRACTALL Consensus Report. J Allergy Clin Immunol. 2006;118:152\u201369.","journal-title":"J Allergy Clin Immunol"},{"key":"927_CR33","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1111\/j.1365-2133.1994.tb08530.x","volume":"131","author":"HC Williams","year":"1994","unstructured":"Williams HC, Burney PG, Hay RJ, Archer CB, Shipley MJ, Hunter JJ, Bingham EA, Finlay AY, Pembroke AC, Graham-Brown RA. The U.K. Working Party\u2019s diagnostic criteria for atopic dermatitis. I. Derivation of a minimum set of discriminators for atopic dermatitis. Br J Dermatol. 1994a;131:383\u201396.","journal-title":"Br J Dermatol"},{"key":"927_CR34","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1111\/j.1365-2133.1994.tb08531.x","volume":"131","author":"HC Williams","year":"1994","unstructured":"Williams HC, Burney PG, Strachan D, Hay RJ. The U.K. Working Party\u2019s diagnostic criteria for atopic dermatitis. II. Observer variation of clinical diagnosis and signs of atopic dermatitis. Br J Dermatol. 1994b;131:397\u2013405.","journal-title":"Br J Dermatol"},{"key":"927_CR35","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1111\/j.1365-2133.1994.tb08532.x","volume":"131","author":"HC Williams","year":"1994","unstructured":"Williams HC, Burney PG, Pembroke AC, et al. The U.K. Working Party\u2019s diagnostic criteria for atopic dermatitis. III. Independent hospital validation. Br J Dermatol. 1994c;131:406\u201316.","journal-title":"Br J Dermatol"},{"key":"927_CR36","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1046\/j.1365-2133.2001.04379.x","volume":"145","author":"H Gu","year":"2001","unstructured":"Gu H, Chen XS, Chen K, Yan Y, Jing H, Chen XQ, Shao CG, Ye GY. Evaluation of diagnostic criteria for atopic dermatitis: validity of the criteria of Williams et al. in a hospital-based setting. Br J Dermatol. 2001;145:428\u201333.","journal-title":"Br J Dermatol"},{"key":"927_CR37","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.sder.2008.05.003","volume":"27","author":"JS Kim","year":"2008","unstructured":"Kim JS. Pediatric atopic dermatitis: the importance of food allergens. Semin Cutan Med Surg. 2008;27:156\u201360.","journal-title":"Semin Cutan Med Surg"},{"issue":"1","key":"927_CR38","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.jpeds.2014.07.062","volume":"166","author":"JA Bird","year":"2015","unstructured":"Bird JA, Crain M, Varshney P. Food allergen panel testing often results in misdiagnosis of food allergy. J Pediatr. 2015;166(1):97\u2013100.","journal-title":"J Pediatr"},{"issue":"2","key":"927_CR39","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.jaip.2015.08.006","volume":"4","author":"A Chang","year":"2016","unstructured":"Chang A, Robison R, Cai M, Singh AM. Natural history of food-triggered atopic dermatitis and development of immediate reactions in children. J Allergy Clin Immunol Pract. 2016;4(2):229\u201336.","journal-title":"J Allergy Clin Immunol Pract"},{"key":"927_CR40","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1016\/j.jaci.2014.08.005","volume":"134","author":"EL Simpson","year":"2014","unstructured":"Simpson EL, Chalmers JR, Hanifin JM, Thomas KS, Cork MJ, McLean WH, Brown SJ, Chen Z, Chen Y, Williams HC. Emollient enhancement of the skin barrier from birth offers effective atopic dermatitis prevention. J Allergy Clin Immunol. 2014;134:818\u201323.","journal-title":"J Allergy Clin Immunol"},{"issue":"4","key":"927_CR41","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1016\/j.jaci.2014.07.060","volume":"134","author":"K Horimukai","year":"2014","unstructured":"Horimukai K, Morita K, Narita M, Kondo M, Kitazawa H, Nozaki M, Shigematsu Y, Yoshida K, Niizeki H, Motomura K, et al. Application of moisturizer to neonates prevents development of atopic dermatitis. J Allergy Clin Immunol. 2014;134(4):824\u201330.","journal-title":"J Allergy Clin Immunol"},{"issue":"2","key":"927_CR42","doi-asserted-by":"crossref","first-page":"e163909","DOI":"10.1001\/jamapediatrics.2016.3909","volume":"171","author":"S Xu","year":"2017","unstructured":"Xu S, Immaneni S, Hazen GB, Silverberg JI, Paller AS, Lio PA. Cost-effectiveness of prophylactic moisturization for atopic dermatitis. JAMA Pediatr. 2017;171(2):e163909.","journal-title":"JAMA Pediatr"},{"issue":"4","key":"927_CR43","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1111\/all.15491","volume":"78","author":"C N\u00ed Chaoimh","year":"2023","unstructured":"N\u00ed Chaoimh C, Lad D, Nico C, Puppels GJ, Wong XFCC, Common JE, Murray DM, et al. Early initiation of short-term emollient use for the prevention of atopic dermatitis in high-risk infants-the STOP-AD randomised controlled trial. Allergy. 2023;78(4):984\u201394.","journal-title":"Allergy"},{"issue":"6","key":"927_CR44","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1111\/all.15116","volume":"77","author":"Y Zhong","year":"2022","unstructured":"Zhong Y, Samuel M, van Bever H, Tham EH. Emollients in infancy to prevent atopic dermatitis: a systematic review and meta-analysis. Allergy. 2022;77(6):1685\u201399.","journal-title":"Allergy"},{"key":"927_CR45","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/S2352-4642(22)00146-8","volume":"6","author":"MJ Ridd","year":"2022","unstructured":"Ridd MJ, Santer M, MacNeill SJ, Sanderson E, Wells S, Webb D, et al. Effectiveness and safety of lotion, cream, gel, and ointment emollients for childhood eczema: a pragmatic, randomised, phase 4, superiority trial. Lancet Child Adolesc Health. 2022;6:522\u201332.","journal-title":"Lancet Child Adolesc Health"},{"issue":"14","key":"927_CR46","doi-asserted-by":"crossref","first-page":"4232","DOI":"10.3390\/jcm11144232","volume":"11","author":"N Papapostolou","year":"2022","unstructured":"Papapostolou N, Xepapadaki P, Gregoriou S, Makris M. Atopic dermatitis and food allergy: a Complex Interplay what we know and what we would like to learn. J Clin Med. 2022;11(14):4232.","journal-title":"J Clin Med"},{"issue":"10344","key":"927_CR47","doi-asserted-by":"crossref","first-page":"2398","DOI":"10.1016\/S0140-6736(22)00687-0","volume":"399","author":"HO Skjerven","year":"2022","unstructured":"Skjerven HO, Lie A, Vettukattil R, Rehbinder EM, LeBlanc M, Asarnoj A, et al. Early food intervention and skin emollients to prevent food allergy in young children (PreventADALL): a factorial, multicentre, cluster-randomised trial. Lancet. 2022;399(10344):2398\u2013411.","journal-title":"Lancet"},{"issue":"4","key":"927_CR48","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1111\/all.15555","volume":"78","author":"LE Bradshaw","year":"2023","unstructured":"Bradshaw LE, Wyatt LA, Brown SJ, Haines RH, Montgomery AA, Perkin MR, et al. Emollients for prevention of atopic dermatitis: 5-year findings from the BEEP randomized trial. Allergy. 2023;78(4):995\u20131006.","journal-title":"Allergy"},{"key":"927_CR49","doi-asserted-by":"crossref","first-page":"720393","DOI":"10.3389\/fimmu.2021.720393","volume":"12","author":"Z Fang","year":"2021","unstructured":"Fang Z, Li L, Zhang H, Zhao J, Lu W, Chen W. Gut microbiota, Probiotics, and their interactions in Prevention and Treatment of atopic dermatitis: a review. Front Immunol. 2021;12:720393.","journal-title":"Front Immunol"},{"key":"927_CR50","doi-asserted-by":"crossref","first-page":"749544","DOI":"10.3389\/fphys.2021.749544","volume":"12","author":"T Hu","year":"2021","unstructured":"Hu T, Dong Y, Yang C, Zhao M, He Q. Pathogenesis of children\u2019s allergic diseases: refocusing the role of the gut microbiota. Front Physiol. 2021;12:749544.","journal-title":"Front Physiol"},{"key":"927_CR51","unstructured":"Araya M, Morelli L, Reid G, Sanders ME, Stanton C, Pineiro M, Ben Embarek P. Guidelines for the evaluation of probiotics in food. Joint FAO\/WHO Working Group Report on drafting guidelines for the evaluation of probiotics in food. 2002; 30:1\u20131."},{"issue":"3","key":"927_CR52","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1007\/s40257-018-0404-3","volume":"20","author":"L Li","year":"2019","unstructured":"Li L, Han Z, Niu X, Zhang G, Jia Y, Zhang S, He C. Probiotic supplementation for Prevention of atopic dermatitis in infants and children: a systematic review and Meta-analysis. Am J Clin Dermatol. 2019;20(3):367\u201377.","journal-title":"Am J Clin Dermatol"},{"issue":"6","key":"927_CR53","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1007\/s40257-022-00723-x","volume":"23","author":"J Voigt","year":"2022","unstructured":"Voigt J, Lele M. Lactobacillus rhamnosus used in the Perinatal Period for the Prevention of atopic dermatitis in infants: a systematic review and Meta-analysis of Randomized trials. Am J Clin Dermatol. 2022;23(6):801\u201311.","journal-title":"Am J Clin Dermatol"},{"issue":"3","key":"927_CR54","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.jdermsci.2019.05.008","volume":"94","author":"M Hide","year":"2019","unstructured":"Hide M, Suzuki T, Tanaka A, Aoki H. Long-term safety and efficacy of rupatadine in Japanese patients with itching due to chronic spontaneous urticaria, dermatitis, or pruritus: a 12-month, multicenter, open-label clinical trial. J Dermatol Sci. 2019;94(3):339\u201345.","journal-title":"J Dermatol Sci"},{"key":"927_CR55","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s13223-019-0375-9","volume":"15","author":"MN Fein","year":"2019","unstructured":"Fein MN, Fischer DA, O\u2019Keefe AW, Sussman GL. CSACI position statement: newer generation H1-antihistamines are safer than first-generation H1-antihistamines and should be the first-line antihistamines for the treatment of allergic rhinitis and urticaria. Allergy Asthma Clin Immunol. 2019;15:61.","journal-title":"Allergy Asthma Clin Immunol"},{"issue":"1","key":"927_CR56","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s40257-016-0240-2","volume":"18","author":"JK Gittler","year":"2017","unstructured":"Gittler JK, Wang JF, Orlow SJ. Bathing and associated treatments in atopic dermatitis. Am J Clin Dermatol. 2017;18(1):45\u201357.","journal-title":"Am J Clin Dermatol"},{"issue":"3","key":"927_CR57","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1016\/j.jaip.2019.10.042","volume":"8","author":"ID Cardona","year":"2020","unstructured":"Cardona ID, Kempe EE, Lary C, Ginder JH, Jain N. Frequent Versus Infrequent bathing in Pediatric atopic dermatitis: a Randomized Clinical Trial. J Allergy Clin Immunol Pract. 2020;8(3):1014\u201321.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"2","key":"927_CR58","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1111\/j.1365-2133.2010.10030.x","volume":"164","author":"J Schmitt","year":"2011","unstructured":"Schmitt J, von Kobyletzki L, Svensson A, Apfelbacher C. Efficacy and tolerability of proactive treatment with topical corticosteroids and calcineurin inhibitors for atopic eczema: systematic review and meta-analysis of randomized controlled trials. Br J Dermatol. 2011;164(2):415\u201328.","journal-title":"Br J Dermatol"},{"issue":"2","key":"927_CR59","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.jaad.2016.02.1228","volume":"75","author":"JA Broeders","year":"2016","unstructured":"Broeders JA, Ahmed Ali U, Fischer G. Systematic review and meta-analysis of randomized clinical trials (RCTs) comparing topical calcineurin inhibitors with topical corticosteroids for atopic dermatitis: a 15-year experience. J Am Acad Dermatol. 2016;75(2):410\u20139.","journal-title":"J Am Acad Dermatol"},{"key":"927_CR60","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1186\/s12887-016-0607-9","volume":"16","author":"EC Siegfried","year":"2016","unstructured":"Siegfried EC, Jaworski JC, Kaiser JD, Hebert AA. Systematic review of published trials: long-term safety of topical corticosteroids and topical calcineurin inhibitors in pediatric patients with atopic dermatitis. BMC Pediatr. 2016;16:75.","journal-title":"BMC Pediatr"},{"key":"927_CR61","unstructured":"LEO Pharma Inc. Protopic (tacrolimus ointment) product monograph. June 27, 2022."},{"key":"927_CR62","unstructured":"Bausch Health, Canada Inc. Pimecrolimus (Elidel cream) product monograph. January 10, 2020."},{"issue":"1","key":"927_CR63","doi-asserted-by":"crossref","first-page":"34","DOI":"10.3109\/09546630903401488","volume":"21","author":"S Reitamo","year":"2010","unstructured":"Reitamo S, Allsopp R. Treatment with twice-weekly tacrolimus ointment in patients with moderate to severe atopic dermatitis: results from two randomized, multicentre, comparative studies. J Dermatolog Treat. 2010;21(1):34\u201344.","journal-title":"J Dermatolog Treat"},{"issue":"2","key":"927_CR64","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.jaad.2020.03.075","volume":"83","author":"AS Paller","year":"2020","unstructured":"Paller AS, F\u00f6lster-Holst R, Chen SC, Diepgen TL, Elmets C, Margolis DJ, Pollock BH. No evidence of increased cancer incidence in children using topical tacrolimus for atopic dermatitis. J Am Acad Dermatol. 2020;83(2):375\u201381.","journal-title":"J Am Acad Dermatol"},{"key":"927_CR65","doi-asserted-by":"crossref","first-page":"299","DOI":"10.2147\/CLEP.S146442","volume":"10","author":"J Castellsague","year":"2018","unstructured":"Castellsague J, Kuiper JG, Potteg\u00e5rd A, Anveden Berglind I, Dedman D, Gutierrez L, et al. A cohort study on the risk of lymphoma and skin cancer in users of topical tacrolimus, pimecrolimus, and corticosteroids (joint European longitudinal lymphoma and skin Cancer evaluation - JOELLE study). Clin Epidemiol. 2018;10:299\u2013310.","journal-title":"Clin Epidemiol"},{"issue":"5","key":"927_CR66","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1111\/j.1525-1470.2010.01223.x","volume":"27","author":"AD McCollum","year":"2010","unstructured":"McCollum AD, Paik A, Eichenfield LF. The safety and efficacy of tacrolimus ointment in pediatric patients with atopic dermatitis. Pediatr Dermatol. 2010;27(5):425\u201336.","journal-title":"Pediatr Dermatol"},{"key":"927_CR67","doi-asserted-by":"crossref","unstructured":"Radovic TC, Kostovic K, Ceovic R, Mokos ZB. Topical Calcineurin Inhibitors and Malignancy Risk. Int J Cancer Manag 2017;10(4):e6173.","DOI":"10.5812\/ijcm.6173"},{"key":"927_CR68","doi-asserted-by":"crossref","unstructured":"Tennis P, Gelfand JM, Rothman KJ. Evaluation of cancer risk related to atopic dermatitis and use of topical calcineurin inhibitors. Br J Dermatol. 2011;165(3):465\u2009\u2013\u200973.","DOI":"10.1111\/j.1365-2133.2011.10363.x"},{"issue":"1","key":"927_CR69","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.clindermatol.2009.04.001","volume":"28","author":"D Tha\u00e7i","year":"2010","unstructured":"Tha\u00e7i D, Salgo R. Malignancy concerns of topical calcineurin inhibitors for atopic dermatitis: facts and controversies. Clin Dermatol. 2010;28(1):52\u20136.","journal-title":"Clin Dermatol"},{"key":"927_CR70","unstructured":"Canadian Dermatology Association, Position Statement TCI. May. 2018. https:\/\/dermatology.ca\/tci-position-statement\/#:~:text=The CDA believes that topical,and ever broadening clinical experience. Accessed September 11, 2023."},{"key":"927_CR71","unstructured":"Pfizer Canada ULC. Eucrisa (crisaborole ointment 2%) product monograph. August 29, 2023."},{"issue":"3","key":"927_CR72","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.jaad.2016.05.046","volume":"75","author":"AS Paller","year":"2016","unstructured":"Paller AS, Tom WL, Lebwohl MG, Blumenthal RL, Boguniewicz M, Call RS, et al. Efficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the topical treatment of atopic dermatitis (AD) in children and adults. J Am Acad Dermatol. 2016;75(3):494\u2013503.","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"927_CR73","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s40257-020-00510-6","volume":"21","author":"J Schlessinger","year":"2020","unstructured":"Schlessinger J, Shepard JS, Gower R, Su JC, Lynde C, Cha A, et al. CARE 1 investigators. Safety, Effectiveness, and Pharmacokinetics of Crisaborole in infants aged 3 to <\u200924 months with mild-to-moderate atopic dermatitis: a phase IV open-label study (CrisADe CARE 1). Am J Clin Dermatol. 2020;21(2):275\u201384.","journal-title":"Am J Clin Dermatol"},{"issue":"4","key":"927_CR74","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.jaad.2017.06.010","volume":"77","author":"LF Eichenfield","year":"2017","unstructured":"Eichenfield LF, Call RS, Forsha DW, Fowler J Jr, Hebert AA, Spellman M, et al. Long-term safety of crisaborole ointment 2% in children and adults with mild to moderate atopic dermatitis. J Am Acad Dermatol. 2017;77(4):641\u2013e6495.","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"927_CR75","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/j.anai.2022.03.024","volume":"128","author":"L Bakaa","year":"2022","unstructured":"Bakaa L, Pernica JM, Couban RJ, Tackett KJ, Burkhart CN, Leins L, et al. Bleach baths for atopic dermatitis: a systematic review and meta-analysis including unpublished data, bayesian interpretation, and GRADE. Ann Allergy Asthma Immunol. 2022;128(6):660\u2013e6689.","journal-title":"Ann Allergy Asthma Immunol"},{"key":"927_CR76","unstructured":"Sanofi-aventis Canada Inc. Dupixent (dupilumab) product monograph. May 1, 2023."},{"key":"927_CR77","unstructured":"Leo Pharma Inc. Adtralza (tralokinumab) product monograph. February 3, 2023."},{"issue":"10013","key":"927_CR78","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/S0140-6736(15)00388-8","volume":"387","author":"D Tha\u00e7i","year":"2016","unstructured":"Tha\u00e7i D, Simpson EL, Beck LA, Bieber T, Blauvelt A, Papp K, et al. Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trial. Lancet. 2016;387(10013):40\u201352.","journal-title":"Lancet"},{"issue":"24","key":"927_CR79","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1056\/NEJMoa1610020","volume":"375","author":"EL Simpson","year":"2016","unstructured":"Simpson EL, Bieber T, Guttman-Yassky E, Beck LA, Blauvelt A, Cork MJ, et al. SOLO 1 and SOLO 2 investigators. Two phase 3 trials of Dupilumab versus Placebo in atopic dermatitis. N Engl J Med. 2016;375(24):2335\u201348.","journal-title":"N Engl J Med"},{"issue":"10086","key":"927_CR80","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.1016\/S0140-6736(17)31191-1","volume":"389","author":"A Blauvelt","year":"2017","unstructured":"Blauvelt A, de Bruin-Weller M, Gooderham M, Cather JC, Weisman J, Pariser D, et al. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial. Lancet. 2017;389(10086):2287\u2013303.","journal-title":"Lancet"},{"issue":"5","key":"927_CR81","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1111\/bjd.16156","volume":"178","author":"M de Bruin-Weller","year":"2018","unstructured":"de Bruin-Weller M, Tha\u00e7i D, Smith CH, Reich K, Cork MJ, Radin A, et al. Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo-controlled, randomized phase III clinical trial (LIBERTY AD CAF\u00c9). Br J Dermatol. 2018;178(5):1083\u2013101.","journal-title":"Br J Dermatol"},{"issue":"2","key":"927_CR82","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1001\/jamadermatol.2019.3617","volume":"156","author":"M Worm","year":"2020","unstructured":"Worm M, Simpson EL, Tha\u00e7i D, Bissonnette R, Lacour JP, Beissert S, et al. Efficacy and safety of multiple dupilumab dose regimens after initial successful treatment in patients with atopic dermatitis: a Randomized Clinical Trial. JAMA Dermatol. 2020;156(2):131\u201343.","journal-title":"JAMA Dermatol"},{"issue":"4","key":"927_CR83","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1007\/s40257-020-00527-x","volume":"21","author":"LA Beck","year":"2020","unstructured":"Beck LA, Tha\u00e7i D, Deleuran M, Blauvelt A, Bissonnette R, de Bruin-Weller M, et al. Dupilumab provides favorable safety and sustained efficacy for up to 3 years in an open-label study of adults with moderate-to-severe atopic dermatitis. Am J Clin Dermatol. 2020;21(4):567\u201377.","journal-title":"Am J Clin Dermatol"},{"key":"927_CR84","doi-asserted-by":"crossref","unstructured":"Beck LA, Bissonnette R, Deleuran M, Nakahara T, Galus R, Khokhar FA et al. Long-term efficacy of dupilumab in adults with moderate to severe AD: results from a 5-year open-label extension study (LIBERTY AD OLE). Presented at the 5th Annual Revolutionizing Atopic Dermatitis (RAD) Conference; Washington, DC, USA; April 29 \u2013May 1, 2023.","DOI":"10.1016\/j.jaci.2023.11.041"},{"issue":"1","key":"927_CR85","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1001\/jamadermatol.2019.3336","volume":"156","author":"EL Simpson","year":"2020","unstructured":"Simpson EL, Paller AS, Siegfried EC, Boguniewicz M, Sher L, Gooderham MJ, et al. Efficacy and safety of Dupilumab in adolescents with uncontrolled moderate to severe atopic dermatitis: a phase 3 Randomized Clinical Trial. JAMA Dermatol. 2020;156(1):44\u201356.","journal-title":"JAMA Dermatol"},{"issue":"5","key":"927_CR86","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1016\/j.jaad.2020.06.054","volume":"83","author":"AS Paller","year":"2020","unstructured":"Paller AS, Siegfried EC, Tha\u00e7i D, Wollenberg A, Cork MJ, Arkwright PD, et al. Efficacy and safety of dupilumab with concomitant topical corticosteroids in children 6 to 11 years old with severe atopic dermatitis: a randomized, double-blinded, placebo-controlled phase 3 trial. J Am Acad Dermatol. 2020;83(5):1282\u201393.","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"927_CR87","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1111\/jdv.16928","volume":"35","author":"AS Paller","year":"2021","unstructured":"Paller AS, Siegfried EC, Simpson EL, Cork MJ, Lockshin B, Kosloski MP, et al. A phase 2, open-label study of single-dose dupilumab in children aged 6 months to <\u20096 years with severe uncontrolled atopic dermatitis: pharmacokinetics, safety and efficacy. J Eur Acad Dermatol Venereol. 2021;35(2):464\u201375.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"10356","key":"927_CR88","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/S0140-6736(22)01539-2","volume":"400","author":"AS Paller","year":"2022","unstructured":"Paller AS, Simpson EL, Siegfried EC, Cork MJ, Wollenberg A, Arkwright PD, et al. Participating investigators. Dupilumab in children aged 6 months to younger than 6 years with uncontrolled atopic dermatitis: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2022;400(10356):908\u201319.","journal-title":"Lancet"},{"issue":"3","key":"927_CR89","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s40257-022-00683-2","volume":"23","author":"A Blauvelt","year":"2022","unstructured":"Blauvelt A, Guttman-Yassky E, Paller AS, Simpson EL, Cork MJ, Weisman J, et al. Long-term efficacy and safety of Dupilumab in adolescents with moderate-to-severe atopic dermatitis: results through Week 52 from a phase III open-label extension Trial (LIBERTY AD PED-OLE). Am J Clin Dermatol. 2022;23(3):365\u201383.","journal-title":"Am J Clin Dermatol"},{"issue":"3","key":"927_CR90","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1111\/bjd.19574","volume":"184","author":"A Wollenberg","year":"2021","unstructured":"Wollenberg A, Blauvelt A, Guttman-Yassky E, Worm M, Lynde C, Lacour JP, et al. ECZTRA 1 and ECZTRA 2 study investigators. Tralokinumab for moderate-to-severe atopic dermatitis: results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2). Br J Dermatol. 2021;184(3):437\u201349.","journal-title":"Br J Dermatol"},{"issue":"3","key":"927_CR91","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1111\/bjd.19573","volume":"184","author":"JI Silverberg","year":"2021","unstructured":"Silverberg JI, Toth D, Bieber T, Alexis AF, Elewski BE, Pink AE, et al. ECZTRA 3 study investigators. Tralokinumab plus topical corticosteroids for the treatment of moderate-to-severe atopic dermatitis: results from the double-blind, randomized, multicentre, placebo-controlled phase III ECZTRA 3 trial. Br J Dermatol. 2021;184(3):450\u201363.","journal-title":"Br J Dermatol"},{"issue":"4","key":"927_CR92","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1007\/s40257-022-00702-2","volume":"23","author":"JI Silverberg","year":"2022","unstructured":"Silverberg JI, Adam DN, Zirwas M, Kalia S, Gutermuth J, Pinter A, Pink AE, Chiricozzi A, Barbarot S, Mark T, Tindberg AM. Tralokinumab Plus Topical corticosteroids as needed provides progressive and sustained efficacy in adults with moderate-to-severe atopic Dermatitis over a 32-Week period: an ECZTRA 3 Post Hoc Analysis. Am J Clin Dermatol. 2022;23(4):547\u201359.","journal-title":"Am J Clin Dermatol"},{"issue":"6","key":"927_CR93","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1001\/jamadermatol.2023.0627","volume":"159","author":"AS Paller","year":"2023","unstructured":"Paller AS, Flohr C, Cork M, Bewley A, Blauvelt A, Hong HC, et al. Efficacy and safety of Tralokinumab in adolescents with moderate to severe atopic dermatitis: the phase 3 ECZTRA 6 Randomized Clinical Trial. JAMA Dermatol. 2023;159(6):596\u2013605.","journal-title":"JAMA Dermatol"},{"issue":"4","key":"927_CR94","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/j.jaad.2022.07.019","volume":"87","author":"A Blauvelt","year":"2022","unstructured":"Blauvelt A, Langley RG, Lacour JP, Toth D, Laquer V, Beissert S, et al. Long-term 2-year safety and efficacy of tralokinumab in adults with moderate-to-severe atopic dermatitis: interim analysis of the ECZTEND open-label extension trial. J Am Acad Dermatol. 2022;87(4):815\u201324.","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"927_CR95","doi-asserted-by":"crossref","first-page":"s143","DOI":"10.25251\/skin.7.supp.143","volume":"7","author":"K Reich","year":"2023","unstructured":"Reich K, Simpson E, Langley R, Warren R, Costanzo A, Saeki H, et al. Tralokinumab demonstrated a consistent safety profile with up to 42 months of treatment in moderate to severe atopic dermatitis: including adverse events of special interest. SKIN: J Cutan Med. 2023;7(2):s143.","journal-title":"SKIN: J Cutan Med"},{"issue":"3","key":"927_CR96","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1111\/bjd.20810","volume":"186","author":"A Wollenberg","year":"2022","unstructured":"Wollenberg A, Beck LA, de Bruin Weller M, Simpson EL, Imafuku S, Boguniewicz M, et al. Conjunctivitis in adult patients with moderate-to-severe atopic dermatitis: results from five tralokinumab clinical trials. Br J Dermatol. 2022;186(3):453\u201365.","journal-title":"Br J Dermatol"},{"key":"927_CR97","unstructured":"Pfizer Canada ULC. CIBINQO (abrocitinib) product monograph. June 30, 2023."},{"key":"927_CR98","unstructured":"AbbVie Corporation. RINVOQ (upadacitinib) product monograph. July 19, 2023."},{"issue":"1","key":"927_CR99","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1042\/BJ20140712","volume":"462","author":"JJ Babon","year":"2014","unstructured":"Babon JJ, Lucet IS, Murphy JM, Nicola NA, Varghese LN. The molecular regulation of Janus kinase (JAK) activation. Biochem J. 2014;462(1):1\u201313.","journal-title":"Biochem J"},{"issue":"10246","key":"927_CR100","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0140-6736(20)30732-7","volume":"396","author":"EL Simpson","year":"2020","unstructured":"Simpson EL, Sinclair R, Forman S, Wollenberg A, Aschoff R, Cork M, et al. Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. Lancet. 2020;396(10246):255\u201366.","journal-title":"Lancet"},{"issue":"8","key":"927_CR101","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1001\/jamadermatol.2020.1406","volume":"156","author":"JI Silverberg","year":"2020","unstructured":"Silverberg JI, Simpson EL, Thyssen JP, Gooderham M, Chan G, Feeney C, Biswas P, Valdez H, DiBonaventura M, Nduaka C, Rojo R. Efficacy and safety of Abrocitinib in patients with moderate-to-severe atopic dermatitis: a Randomized Clinical Trial. JAMA Dermatol. 2020;156(8):863\u201373.","journal-title":"JAMA Dermatol"},{"issue":"12","key":"927_CR102","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1056\/NEJMoa2019380","volume":"384","author":"T Bieber","year":"2021","unstructured":"Bieber T, Simpson EL, Silverberg JI, Tha\u00e7i D, Paul C, Pink AE, et al. JADE COMPARE investigators. Abrocitinib versus Placebo or Dupilumab for atopic dermatitis. N Engl J Med. 2021;384(12):1101\u201312.","journal-title":"N Engl J Med"},{"issue":"10","key":"927_CR103","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1001\/jamadermatol.2021.2830","volume":"157","author":"LF Eichenfield","year":"2021","unstructured":"Eichenfield LF, Flohr C, Sidbury R, Siegfried E, Szalai Z, Galus R, et al. Efficacy and safety of Abrocitinib in Combination with topical therapy in adolescents with moderate-to-severe atopic dermatitis: the JADE TEEN Randomized Clinical Trial. JAMA Dermatol. 2021;157(10):1165\u201373.","journal-title":"JAMA Dermatol"},{"issue":"1","key":"927_CR104","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.jaad.2021.05.075","volume":"86","author":"A Blauvelt","year":"2022","unstructured":"Blauvelt A, Silverberg JI, Lynde CW, Bieber T, Eisman S, Zdybski J, et al. Abrocitinib induction, randomized withdrawal, and retreatment in patients with moderate-to-severe atopic dermatitis: results from the JAK1 atopic dermatitis efficacy and safety (JADE) REGIMEN phase 3 trial. J Am Acad Dermatol. 2022;86(1):104\u201312.","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"927_CR105","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1007\/s40257-021-00618-3","volume":"22","author":"EL Simpson","year":"2021","unstructured":"Simpson EL, Silverberg JI, Nosbaum A, Winthrop KL, Guttman-Yassky E, Hoffmeister KM, et al. Integrated Safety Analysis of Abrocitinib for the treatment of moderate-to-severe atopic Dermatitis from the phase II and Phase III Clinical Trial Program. Am J Clin Dermatol. 2021;22(5):693\u2013707.","journal-title":"Am J Clin Dermatol"},{"issue":"10290","key":"927_CR106","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1016\/S0140-6736(21)00588-2","volume":"397","author":"E Guttman-Yassky","year":"2021","unstructured":"Guttman-Yassky E, Teixeira HD, Simpson EL, Papp KA, Pangan AL, Blauvelt A, et al. Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (measure up 1 and measure up 2): results from two replicate double-blind, randomised controlled phase 3 trials. Lancet. 2021;397(10290):2151\u201368.","journal-title":"Lancet"},{"issue":"10290","key":"927_CR107","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1016\/S0140-6736(21)00589-4","volume":"397","author":"K Reich","year":"2021","unstructured":"Reich K, Teixeira HD, de Bruin-Weller M, Bieber T, Soong W, Kabashima K, et al. Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD up): results from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2021;397(10290):2169\u201381.","journal-title":"Lancet"},{"issue":"9","key":"927_CR108","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1001\/jamadermatol.2021.3023","volume":"157","author":"A Blauvelt","year":"2021","unstructured":"Blauvelt A, Teixeira HD, Simpson EL, Costanzo A, De Bruin-Weller M, Barbarot S, et al. Efficacy and safety of Upadacitinib vs Dupilumab in adults with moderate-to-severe atopic dermatitis: a Randomized Clinical Trial. JAMA Dermatol. 2021;157(9):1047\u201355.","journal-title":"JAMA Dermatol"},{"issue":"10348","key":"927_CR109","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/S0140-6736(22)01199-0","volume":"400","author":"K Reich","year":"2022","unstructured":"Reich K, Thyssen JP, Blauvelt A, Eyerich K, Soong W, Rice ZP, et al. Efficacy and safety of abrocitinib versus dupilumab in adults with moderate-to-severe atopic dermatitis: a randomised, double-blind, multicentre phase 3 trial. Lancet. 2022;400(10348):273\u201382.","journal-title":"Lancet"},{"issue":"4","key":"927_CR110","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1111\/j.1398-9995.2009.02325.x","volume":"65","author":"MK Church","year":"2010","unstructured":"Church MK, Maurer M, Simons FE, Bindslev-Jensen C, van Cauwenberge P, Bousquet J, et al. Global allergy and Asthma European Network. Risk of first-generation H(1)-antihistamines: a GA(2)LEN position paper. Allergy. 2010;65(4):459\u201366.","journal-title":"Allergy"},{"key":"927_CR111","unstructured":"Canadian Society of. Allergy and Immunology (CSACI). Immunotherapy Manual. 2024."},{"issue":"1 Suppl","key":"927_CR112","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.jaci.2010.09.034","volume":"127","author":"L Cox","year":"2011","unstructured":"Cox L, Nelson H, Lockey R, Calabria C, Chacko T, Finegold I, Nelson M, Weber R, Bernstein DI, Blessing-Moore J, Khan DA, Lang DM, Nicklas RA, Oppenheimer J, Portnoy JM, Randolph C, Schuller DE, Spector SL, Tilles S, Wallace D. Allergen Immunotherapy: a practice parameter third update. J Allergy Clin Immunol. 2011;127(1 Suppl):S1\u201355.","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"927_CR113","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.jaci.2013.02.044","volume":"132","author":"JM Bae","year":"2013","unstructured":"Bae JM, Choi YY, Park CO, Chung KY, Lee KH. Efficacy of allergen-specific immunotherapy for atopic dermatitis: a systematic review and meta-analysis of randomized controlled trials. J Allergy Clin Immunol. 2013;132(1):110\u20137.","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"927_CR114","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.jaci.2022.09.020","volume":"151","author":"JJ Yepes-Nu\u00f1ez","year":"2023","unstructured":"Yepes-Nu\u00f1ez JJ, Guyatt GH, G\u00f3mez-Escobar LG, P\u00e9rez-Herrera LC, Chu AWL, Ceccaci R, et al. Allergen Immunotherapy for atopic dermatitis: systematic review and meta-analysis of benefits and harms. J Allergy Clin Immunol. 2023;151(1):147\u201358.","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"927_CR115","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1111\/bjd.15165","volume":"177","author":"G Gonz\u00e1lez-L\u00f3pez","year":"2017","unstructured":"Gonz\u00e1lez-L\u00f3pez G, Ceballos-Rodr\u00edguez RM, Gonz\u00e1lez-L\u00f3pez JJ, Feito Rodr\u00edguezM, Herranz-Pinto P. Efficacy and safety of wet wrap therapy for patients with atopic dermatitis: a systematic review and meta-analysis. Br J Dermatol. 2017;177(3):688\u201395.","journal-title":"Br J Dermatol"},{"issue":"Suppl 2","key":"927_CR116","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/s13223-018-0281-6","volume":"14","author":"S Kapur","year":"2018","unstructured":"Kapur S, Watson W, Carr S. Atopic dermatitis. Allergy Asthma Clin Immunol. 2018;14(Suppl 2):52.","journal-title":"Allergy Asthma Clin Immunol"}],"container-title":["Allergy, Asthma &amp; Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13223-024-00927-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13223-024-00927-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13223-024-00927-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T15:43:52Z","timestamp":1748360632000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacijournal.biomedcentral.com\/articles\/10.1186\/s13223-024-00927-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,9]]},"references-count":116,"journal-issue":{"issue":"S3","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["927"],"URL":"https:\/\/doi.org\/10.1186\/s13223-024-00927-2","relation":{},"ISSN":["1710-1492"],"issn-type":[{"value":"1710-1492","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,9]]},"assertion":[{"value":"27 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethics approval and consent to participate are not applicable to this review article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Dr. Stuart Carr has participated in speaker\u2019s bureaus and advisory boards with Sanofi. Dr. Rebecca Pratt has received consulting fees and honoraria for continuing education sessions from Merck, Medexus, Novartis, Astrazenca, GSK, Sanofi, Covis, Aralez, Stallergens-Greer, Bausch, AbbVie and ALK. Dr. Fred White: none. Dr. Wade Watson is medical advisor for Food Allergy Canada.None of the authors received any incentive or funding for the preparation or review of the manuscript.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This article has been published as part of Allergy, Asthma & Clinical Immunology, Volume 20 Supplement 03, 2024: Practical Guide for Allergy and Immunology in Canada 2024. The full contents of the supplement are available at .","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"About this supplement"}}],"article-number":"63"}}